BODE INDEX IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN COMBINATION WITH HYPERTENSIVE HEART DISEASE

Authors:

Abstract:

The prognostic potential of the BODE index in assessing future cardiovascular risk in patients with chronic obstructive pulmonary disease in combination with hypertensive heart disease based on left ventricular geometry has been established. Comparing the BODE index results depending on the type of left ventricular remodeling, a significant (p=0.032) increase in the index was determined in patients with prognostically unfavorable left ventricular remodeling compared to relatively favorable types – 1.73±0.45 scores vs. 1.45±0.63 scores. Patients with comorbid conditions showed a significant decrease in exercise tolerance and a tendency to desaturation. In order to increase the BODE index sensitivity in predicting the course of chronic obstructive pulmonary disease of the GOLD 2 grade, group B in combination with stage II hypertension, we propose to consider the presence of desaturation. That is, to consider a decrease in the saturation levels during a six-minute walk test from the initial value ≥4% as one of the prognostically unfavorable criteria.

Keywords:

chronic obstructive pulmonary disease hypertensive heart disease BODE index echocardiography left ventricular geometry

References:

1. Abdel-Aaty HE-S, Zamzam MA, Azab NY, El Wahsh RAER, El Beltagy SA. Comparison of GOLD classification and modified BODE index as staging systems of COPD. Egyptian Journal of Chest Diseases and Tuberculosis. 2014; 63:821-28. DOI: 10.1016/j.ejcdt.2014.06.008.
2. Anzueto A, Heijdra Y, Hurst JR, editors. Controversies in COPD: ERS Monograph. Plymouth, UK: published by European Respiratory Society; 2015. 333 p. doi: 10.1183/2312508X.10008315.
3. Celli BR. Predictors of mortality in COPD. Respir Med. 2010 Jun; 104(6):773-9. PMID: 20417082, DOI: 10.1016/j.rmed.2009.12.017.
4. Enright PL. Oxygen desaturation during a 6-min walk identifies a COPD phenotype with an increased risk of morbidity and mortality. Eur Respir J. 2016 Jul; 48(1):1-2. PMID: 27365500, DOI: 10.1183/13993003.00884-2016.
5. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31(7):1281-357. PMID: 23817082, DOI: 10.1097/01.hjh.0000431740.32696.cc.
6. Soler-Cataluña JJ, Marzo M, Catalán P, Miralles C, Alcazar B, Miravitlles M. Validation of clinical control in COPD as a new tool for optimizing treatment. Int J Chron Obstruct Pulmon Dis. 2018 Nov 14; 13:3719-3731. PMID: 30532528, DOI: 10.2147/COPD.S178149.
7. Williams JE, Green RH, Warrington V, Steiner MC, Morgan MD, Singh SJ. Development of the i-BODE: validation of the incremental shuttle walking test within the BODE index. Respir Med. 2012 Mar; 106(3):390-6. PMID: 21978938, DOI: 10.1016/j.rmed.2011.09.005.

Publication:

«World of Medicine and Biology» Vol. 16 No. 74 (2020) , с. 64-67
УДК [616.24-007.272-036.12-057+616.12-008.331.1]-073.432.19:612.176

DOI:

https://doi.org/10.26724/2079-8334-2020-4-74-64-67